Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Cytarabine in High-risk MDS and Poor-prognosis AML
NCT00195104Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2003
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by Weill Cornell Medicine. Primary endpoints: Maximum Tolerated Dose and Dose-Limiting Toxicity at 24 days and Safety and Tolerability at 4 weeks. Started Sep 2003; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00195104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00195104.